PareshDandonaMDPhysician

Endocrinology • Buffalo, NY

Distinguished Professor, Head Division of Endocrinology, State University of New York at Buffalo

Join to view full profile

Dr. Dandona is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dandona's full profile

Already have an account?

Office
3 Gates Cir
Diabetes Center of Wny
Buffalo, NY 14209
Phone+1 716-887-4069

Fax+1 716-887-4773

Education & Training

All India Institute of Medical SciencesClass of 1965

Certifications & Licensure

NY State Medical License 1994 - 2026

Awards, Honors, & Recognition

Buffalo Spree Magazine Castle Connolly, 2006, 2008, 2013-2014
Fellow (FACE) American Association of Clinical Endocrinology
Fellow (FACC) American College of Cardiology

Clinical Trials

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism Start of enrollment: 2006 Jul 01
Completed
Phase 4
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. Start of enrollment: 2007 Feb 01
Terminated
Phase 4
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism Start of enrollment: 2007 Jun 01
Terminated
Not Applicable
The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects Start of enrollment: 2008 Mar 01
Completed
Not Applicable
Testosterone Replacement in Men With Diabetes and Obesity Start of enrollment: 2010 May 01
Completed
Phase 4
The Suppression of Toll Like Receptors by Insulin Start of enrollment: 2008 Sep 01
Completed
Not Applicable
Exeantide in Type 2 Diabetes on Insulin Start of enrollment: 2008 Apr 01
Completed
Phase 2
Resveratrol in Type2 Diabetes and Obesity Start of enrollment: 2008 Dec 01
Terminated
Not Applicable
Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study
Completed
Phase 4
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus Start of enrollment: 2010 Oct 01
Completed
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes Start of enrollment: 2012 Nov 01
Withdrawn
Phase 3
Liraglutide in Type 1 Diabetes Start of enrollment: 2012 Nov 01
Completed
Phase 3
Liraglutide in the Treatment of Type 1 Diabetes Mellitus Start of enrollment: 2012 Nov 01
Completed
Phase 3
Sitagliptin in Type I Diabetic Patients Start of enrollment: 2011 Jun 01
Withdrawn
Not Applicable
Liraglutide In Overweight Patients With Type 1 Diabetes Start of enrollment: 2012 Dec 01
Completed
Phase 3
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin Start of enrollment: 2015 Nov 01
Completed
Phase 4
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes Start of enrollment: 2016 Mar 01
Completed
Not Applicable
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes Start of enrollment: 2016 Nov 01
Completed
Not Applicable
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes Start of enrollment: 2017 Jan 10
Terminated
Phase 4
Triple Therapy in T1DM Start of enrollment: 2019 May 01
Recruiting
Phase 2, Phase 3
Anti-inflammatory Effects of the Fiber Start of enrollment: 2016 Jun 14
Unknown status
Not Applicable
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Diabetes surpasses obesity as a risk factor for low serum testosterone level.
Samir H Assaad Khalil, Paresh Dandona, Nermin A Osman, Ramy Samir Assaad, Basma Tayseer Abdalla Zaitoon
Diabetology & Metabolic Syndrome. 2024-06-28
Glucose ingestion does not lower testosterone concentrations in men on testosterone therapy.
Sandeep Dhindsa, Husam Ghanim, Michael J McPhaul, Amit K Ghoshal, Paresh Dandona
Journal of Investigative Medicine. 2024-06-01
Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon.
Mahmoud Nassar, Ajay Chaudhuri, Husam Ghanim, Paresh Dandona
World Journal of Diabetes. 2024-02-15

Journal Articles

Hypogonadotropic Hypogonadism in Men with Diabesity
Sandeep Dhindsa, Paresh Dandona, Diabetes Care

Lectures

New Treatments for Type 1 Diabetes and the Pathophysiology of Microvascular Complications
ENDO 2019 - New Orleans, LA - 3/24/2019

Press Mentions

Deficiency That Affects Nearly 40% of Men over 45 May Double Risk of Severe Covid - StudySeptember 10th, 2022
Low Testosterone May Raise Risk of COVID HospitalizationSeptember 9th, 2022
Blood Compound ‘Lac-Fe’ May Help Treat Obesity, Study SuggestsJune 21st, 2022
Join now to see all

Grant Support

Testosterone Effects On Insulin Sensitivity &Inflammation In T2dm And ObesityNational Institute Of Diabetes And Digestive And Kidney Diseases2011
Hypogonadotropic Hypogonadism, Insulin Sensitivity And Inflammation In Type 2 DIANational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
Inflammation In Obesity: Modulation By Weight LossNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2009